Doublet regimen active, in ovarian cancer

Haluska, Paul
April 2008
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p32
The article discusses research on carboplatin and pemetrexed and their effect on ovarian cancer treatment. It references a study presented by Ursula Matulonis, MD, assistant professor of medicine at Harvard Medical School, on 44 patients administered pemetrexed followed every 21 days by carboplatin for up to six cycles. Results showed that the double regimen was well tolerated and was active in platinum-sensitive recurrent ovarian cancer.


Related Articles

  • Chimiothérapie intrapéritonéale dans les cancers de l’ovaire. Geay, J.-F.; Pujade-Lauraine, E.; Guastalla, J.-P. // Oncologie;feb2006, Vol. 8 Issue 2, p145 

    Due to the predominance of peritoneal relapses in the evolution of ovarian cancer, intraperitonial (IP) chemotherapy was the object of sustained interest in the 1980s before becoming obsolete. Recently in France intraperitoneal hyperthermic chemotherapy (IPHC) has been put to the forefront,...

  • Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation. ÖZGÜL, Nejat; KÖSE, Mehmet Faruk; KESKIN, Hüseyin Levent; TURAN, Ahmet Taner; KARALÖK, Mustafa Alper; ÜREYEN, Isin; BORAN, Nurettin; TULUNAY, Hakki Gökhan // Turkish Journal of Medical Sciences;Apr2014, Vol. 44 Issue 2, p212 

    Aim: To evaluate the effectiveness of the addition of epirubicin to conventional chemotherapy as a first-line therapy for stage III-IV epithelial ovarian cancer. Materials and methods: A total of 132 patients who had undergone primary cytoreductive surgery between January 1998 and March 2003...

  • First-line platinum-taxane combo cost effective in ovarian cancer.  // PharmacoEconomics & Outcomes News;Jul2015, Vol. 731 Issue 1, p16 

    The article reports on a study which demonstrates the cost effectiveness of the first-line treatment using standard platinum-taxane combination chemotherapy in ovarian cancer.

  • Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. Guardiola, Emmanuel; Delroeux, Delphine; Heyd, Bruno; Combe, Marielle; Lorgis, Veronique; Demarchi, Martin; Stein, Ulrich; Royer, Bernard; Chauffert, Bruno; Pivot, Xavier // World Journal of Surgical Oncology;2009, Vol. 7, p1 

    Background: Intra-peritoneal (i.p.) chemotherapy is an encouraging treatment option for ovarian cancer with peritoneum involvement in addition with intravenous (i.v.) chemotherapy. Intraoperative i.p. chemotherapy is an interesting method of administration by enhancing the diffusion of...

  • Surgical debulking of ovarian cancer: Past, present, or future? SCHORGE, JOHN O.; GOODMAN, ANNEKATHRYN // Contemporary OB/GYN;Jul2010, Vol. 55 Issue 7, p36 

    For patients with ovarian cancer who are candidates for debulking, the question remains: debulking with adjuvant chemotherapy or chemotherapy with interval de bulking. This review examines the clinical literature and offers practical recommendations.

  • Cost of advanced ovarian cancer: PDS vs NACT.  // PharmacoEconomics & Outcomes News;Apr2015, Vol. 726 Issue 1, p13 

    The article offers information on a study conducted in the U.S. that compared the treatment costs of primary debulking surgery (PDS) and neo-adjuvant chemotherapy (NACT) used on women with ovarian cancer.

  • Erratum to: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Crane, Lucia; Arts, Henriette; Oosten, Marleen; Low, Philip; Zee, Ate; Dam, Gooitzen; Bart, Joost // Cellular Oncology (2211-3428);Jun2012, Vol. 35 Issue 3, p229 

    A correction to the article "The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer" that was published in the June 2011 issue is presented.

  • Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Du, Xianglin; Parikh, Rohan; Lairson, David; Giordano, Sharon; Cen, Putao // Medical Oncology;Mar2013, Vol. 30 Issue 1, p1 

    The aim was to compare the two most commonly recommended chemotherapy regimens (platinum-based chemotherapy and platinum-taxane combination) with non-platinum-based chemotherapy and those with no chemotherapy in a large nationwide and population-based cohort of patients with ovarian cancer with...

  • Successful complete regression of isolated intramedullary spinal cord metastases from epithelial ovarian carcinoma with chemotherapy and radiotherapy. Bakshi, A.; Biswas, G.; Deshmukh, C.; Prasad, N.; Nair, R.; Parikh, P. M. // Indian Journal of Cancer;Jul-Sep2006, Vol. 43 Issue 3, p136 

    Advances in the management of ovarian cancer by use of aggressive surgery and effective platinum-based chemotherapy have prolonged survival; this may have resulted in an alteration of the metastatic pattern of the disease and spread to unusual sites (e.g, CNS) has become more common. Also, with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics